Their paper, “Interplay Between VEGF-A and cMET Signaling in Human Vestibular Schwannomas and Schwann Cells,” by Sonam Dilwali, B.S., Daniel Roberts, M.D., Ph.D., and Konstantina M. Stankovic, M.D., Ph.D., FACS, is online in the Feb. 20 issue of Cancer Biology and Therapy. …
The findings were published online by the journal Nature Medicine. Ovarian cancer is divided into four different histological subtypes. …
“This vaccine is a wonderful example of applying biomaterials to new questions and issues in medicine,” says David Mooney, Ph.D., a professor of bioengineering at Harvard University in the School of Engineering and Applied Sciences, whose lab developed the vaccine. The project was co-led by Jaeyun Kim, Ph.D. and Aileen Li, a doctoral student in the Mooney lab. Their findings were published in the December 8, 2014 issue of Nature Biotechnology. …
An increasing number of head and neck cancers are caused by a virus, the human papilloma virus (HPV). Using tissue from HPV-positive and HPV-negative (largely linked to smoking) HNSCC tumors, researchers from institutions around the country referenced The Cancer Genome Atlas to develop a comprehensive assessment of alterations, or oncogenes, that could play a role in how the tumors develop and metastasize, said Wendell Yarbrough, M.D., section chief of otolaryngology at Yale School of Medicine and Clinical Program Leader of the Head & Neck Cancer Program at Smilow Cancer Hospital at Yale-New Haven. “To make the progress we envision with personalized medicine, we first have to understand what’s driving these tumors, and this is one of the first studies to do this,” said Yarbrough, an author on the study. …
The research reveals a more explicit role about the symbiotic relationship humans have with the various bacteria that inhabit our body and their role during tumor progression. “Our research indicates that interactions between the helpful bacteria in our bodies and immune cells at places situated away from tumors influence systemic responses in the host that alter how these tumors are able to progress,” said Jos� Conejo-Garcia, M.D., Ph.D., Associate Professor and Program Leader in the Tumor Microenvironment and Metastasis Program at The Wistar Institute and lead author of the study…
A total of 69,764 women diagnosed with endometrial cancer between 2000 and 2010 were included in this study of public-use data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program. …
And since trastuzumab, and not chemotherapy alone, is the standard of care for the HER2-positive sub-class of breast cancer, there is no need to test for these lymphocytes in HER2-positive patients in order to predict outcome, say researchers from Mayo Clinic in Florida. These findings, presented at the 2014 San Antonio Breast Cancer Symposium, don’t mean that immune function in this class of cancer isn’t important — just that it is likely more complicated than measuring the number of these lymphocytes, says the study’s lead author, Edith A. Perez, M.D., deputy director at large, Mayo Clinic Cancer Center, and director of the Breast Cancer Translational Genomics Program at Mayo Clinic in Florida. “Researchers are really interested in the different components of the immune system as a predictor of the natural history of breast cancer and benefit from different therapies, but it may be that when trastuzumab is used, it is the function of the immune system and not the number of lymphocytes that is important,” Dr. …
Their research appears in The FASEB Journal. “We hope that this study will lead to novel treatment approaches for women diagnosed with late-stage ovarian cancer,” said Jim Petrik, a Guelph biomedical sciences professor. He worked on the study with Guelph graduate student Samantha Russell and cancer researchers from Harvard Medical School…
A University of Utah-led study reports that cancers select against a protein complex called the mitochondrial pyruvate carrier (MPC), and re-introduction of MPC in colon cancer cells impairs several properties of cancer, including growth. The research, which appears online on Oct…
The research, led by John Wagner, Jr., M.D., director of the Pediatric Blood and Marrow Transplantation program at the University of Minnesota and a researcher in the Masonic Cancer Center, University of Minnesota, compared outcomes in children with acute leukemia and myelodysplastic syndrome who received transplants of either one or two units of partially matched cord blood. The study was conducted at multiple sites nationwide, between December 2006 and February 2012. Coordinating the study was the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) in collaboration with the Pediatric Blood and Marrow Transplant Consortium and the Children’s Oncology Group. …